Ayahuasca Preparations and Serotonin Reuptake Inhibitors: A Potential Combination for Severe Adverse Interactions
James C. Callaway, Charles S. Grob
Journal of Psychoactive Drugs December 1, 1998 DOI: 10.1080/02791072.1998.10399712 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Ayahuasca Serotonin |
| Keywords | Hallucinogen Pharmacology Reuptake inhibitor Serotonin syndrome Peganum harmala Monoamine oxidase inhibitor |
| Citations | 134 |
| Key findings | Combining ayahuasca with SSRI antidepressants may induce serotonin syndrome with potentially grave outcome. |
Abstract
The Amazonian psychoactive plant beverage ayahuasca has attracted increasing interest in recent years. Little attention has been given, however, to potentially dangerous interactions with other drugs. In particular, the interaction between the potent monoamine oxidase-inhibiting harmala alkaloids in ayahuasca and the selective serotonin reuptake inhibitor (SSRI) class of antidepressants may induce a serotonin syndrome with potentially grave outcome. Caution is advised when combining ayahuasca with certain pharmaceutical drugs.
Comparable studies
Other narrative reviews on ayahuasca, most cited first.
Citations in the library
Cited by 89
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers Psychopharmacology February 22, 2001
- Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids Addiction December 20, 2006
- The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization. Frontiers in Pharmacology March 2, 2016
- The globalization of ayahuasca: Harm reduction or benefit maximization? International Journal of Drug Policy December 5, 2006
and 84 more in the library